GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Galderma Group AG (FRA:PY30) » Definitions » Total Current Assets

Galderma Group AG (FRA:PY30) Total Current Assets : €1,760 Mil (As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Galderma Group AG Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Galderma Group AG's total current assets for the quarter that ended in Dec. 2024 was €1,760 Mil.

Galderma Group AG Total Current Assets Historical Data

The historical data trend for Galderma Group AG's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galderma Group AG Total Current Assets Chart

Galderma Group AG Annual Data
Trend Dec23 Dec24
Total Current Assets
1,481.87 1,760.07

Galderma Group AG Semi-Annual Data
Jun23 Dec23 Jun24 Dec24
Total Current Assets - 1,481.87 1,665.70 1,760.07

Galderma Group AG Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Galderma Group AG's Total Current Assets for the fiscal year that ended in Dec. 2024 is calculated as

Total Current Assets=Cash, Cash Equivalents, Marketable Securities+Total Receivables+Total Inventories+Other Current Assets
=436.435+869.05+384.865+69.715
=1,760

Galderma Group AG's Total Current Assets for the quarter that ended in Dec. 2024 is calculated as

Total Current Assets=Cash, Cash Equivalents, Marketable Securities+Total Receivables+Total Inventories+Other Current Assets
=436.435+869.05+384.865+69.715
=1,760

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Galderma Group AG  (FRA:PY30) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Galderma Group AG's Liquidation Value for the quarter that ended in Dec. 2024 is

Liquidation value
= Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=436.435-4609.785+0.75 * 720.07+0.5 * 384.865
=-3,441

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Galderma Group AG Total Current Assets Related Terms

Thank you for viewing the detailed overview of Galderma Group AG's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Galderma Group AG Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Galderma Group AG (FRA:PY30) » Definitions » Total Current Assets
Comparable Companies
XSWX:SDZ XSWX:PPGN XSWX:SFZN XSWX:CURN ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN NSE:DIVISLAB HKSE:03692 XTAE:TEVA SHSE:688506 BOM:500087 TSE:4507 SZSE:000538 UTHR NSE:TORNTPHARM BOM:543904 BOM:500124
Traded in Other Exchanges
GALDY:USA GDERF:USA GALDz:UK GALD:Switzerland
Address
Zahlerweg 10, Zug, CHE, 6300
Website
https://www.galderma.com
Galderma was formed in 1981 as a joint venture between Nestle and L'Oreal. It subsequently became a subsidiary of Nestle, called Nestle Skin Health, before being carved out and launched as a standalone company in 2019, acquired by a consortium led by Sweden-based EQT fund. The company went public in March 2024 and is listed on the SIX Swiss exchange. Galderma's science-based portfolio spans multiple dermatology categories, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. It derives around 45% of net sales from the US and employs around 6,600 people.

Galderma Group AG Headlines

No Headlines